The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis
Study Type
OBSERVATIONAL
Enrollment
1,010
Proportion of patients with of Transthyretin (TTR) mutations
Blood will be sequenced for the presence of TTR gene mutations
Time frame: Baseline
Assessment of the presence of amyloid in tissue
An optional fine-needle aspirate of the abdominal fat pad will be collected
Time frame: Day 30
Quantification of biomarkers of cardiac function in serum
Biomarkers that assess cardiac function will be quantified from serum
Time frame: Day 30
Measurement of echocardiogram parameters
Cardiac structure and function will be measured by echocardiogram
Time frame: Day 30
New York Heart Association (NYHA) Functional Classification
NYHA Functional Classification will be determined
Time frame: Day 30
Results from 6-Minute Walk Test
Total distance walked in 6 minutes will be measured
Time frame: Day 30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Trial Site
Little Rock, Arkansas, United States
Clinical Trial Site
Bakersfield, California, United States
Clinical Trial Site
La Mesa, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Torrance, California, United States
Clinical Trial Site
Aurora, Colorado, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
...and 48 more locations